Vertex’s Suzetrigine Disappoints In Phase II Pain Study, But Phase III Planning Under Way
Acute Pain Approval Decision Due 30 January
The NaV1.8 inhibitor showed a statistically significant change from baseline in lumbosacral radiculopathy pain, but it was the same as the reduction in the study’s placebo arm.
